Fourth Ring Pharmaceuticals: Xuanzhu Biotechnology's innovative drug Deluoac tablets approved for market listing

Announcement from Sihuan Pharmaceuticals: Xuanzhu Biotech, a subsidiary of the group, independently developed an innovative drug, Dilorac, an ALK inhibitor. It has been approved by the China National Medical Products Administration for the treatment of ALK-positive advanced non-small cell lung cancer. Dilorac has four core advantages, including rapid onset of action, excellent tumor inhibition intensity, lasting relief, and significant survival benefits. According to Zhishi Consulting data, in 2024, there will be 91,200 ALK-positive NSCLC patients in China, and it is estimated to reach 121,700 by 2032, with a compound annual growth rate of 3.7%. In 2024, the market size of ALK inhibitors in China is approximately 4.7 billion yuan, and it is forecasted to increase to 8.9 billion yuan by 2032, with a compound annual growth rate of 8.3%.